Show simple item record

dc.contributor.authorPowles, T
dc.contributor.authorBrown, J
dc.contributor.authorLarkin, J
dc.contributor.authorJones, R
dc.contributor.authorRalph, C
dc.contributor.authorHawkins, Robert E
dc.contributor.authorChowdhury, S
dc.contributor.authorBoleti, E
dc.contributor.authorBhal, A
dc.contributor.authorFife, K
dc.contributor.authorWebb, A
dc.contributor.authorCrabb, S
dc.contributor.authorGeldart, T
dc.contributor.authorHill, R
dc.contributor.authorDunlop, J
dc.contributor.authorHall, P
dc.contributor.authorMcLaren, D
dc.contributor.authorAckerman, C
dc.contributor.authorBeltran, L
dc.contributor.authorNathan, P
dc.date.accessioned2016-03-30T09:37:15Zen
dc.date.available2016-03-30T09:37:15Zen
dc.date.issued2016-01-22en
dc.identifier.citationA randomised, double-blind phase II study evaluating cediranib vs cediranib and saracatinib in patients with relapsed metastatic clear cell renal cancer (COSAK). 2016: Ann Oncolen
dc.identifier.issn1569-8041en
dc.identifier.pmid26802156en
dc.identifier.doi10.1093/annonc/mdw014en
dc.identifier.urihttp://hdl.handle.net/10541/603960en
dc.description.abstractPreclinical work suggests Src proteins have a role in the development of resistance to vascular endothelial growth factor (VEGF) targeted therapy in metastatic clear cell renal cancer (mRCC). This hypothesis was tested in this trial using the SRC inhibitor saracatinib and the VEGF inhibitor cediranib.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen
dc.titleA randomised, double-blind phase II study evaluating cediranib vs cediranib and saracatinib in patients with relapsed metastatic clear cell renal cancer (COSAK).en
dc.typeArticleen
dc.contributor.departmentThe Royal Free NHS Foundation Trust, London, UK Barts Cancer Institute, CRUK Experiment Cancer Medicine Centreen
dc.identifier.journalAnnals of Oncologyen
html.description.abstractPreclinical work suggests Src proteins have a role in the development of resistance to vascular endothelial growth factor (VEGF) targeted therapy in metastatic clear cell renal cancer (mRCC). This hypothesis was tested in this trial using the SRC inhibitor saracatinib and the VEGF inhibitor cediranib.


This item appears in the following Collection(s)

Show simple item record